Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period from May 1, 2008, to October 31, 2008, with a report date of November 11, 2008. The document serves as a Block Listing Six Monthly Return, detailing the status of unallotted securities across nine distinct share option schemes.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document is strictly limited to equity compensation data.
| Share Option Scheme | Securities Issued/Allotted (Period) | Balance Unallotted (End of Period) |
|---|---|---|
| GlaxoSmithKline Share Option Plan - Ordinary Shares | 348,670 | 5,997,825 |
| GlaxoSmithKline Share Option Plan - ADS | 2,008,762 | 6,397,824 |
| GlaxoSmithKline Savings Related Share Option Scheme | 129,432 | 6,187,650 |
| Glaxo Wellcome UK Share Option Scheme | 0 | 5,119,750 |
| Glaxo Wellcome International Share Option Scheme | 0 | 13,267,156 |
| Glaxo Wellcome 1999 Share Option Plan | 0 | 1,040,000 |
| SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares | 0 | 163,606 |
| SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS | 0 | 275,420 |
| SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary | 0 | 100,000 |
Material Changes
No increases were applied for to any block schemes during the reporting period. Issuances occurred in three specific plans:
- GlaxoSmithKline Share Option Plan - ADS: The largest issuance volume at 2,008,762 securities.
- GlaxoSmithKline Share Option Plan - Ordinary Shares: 348,670 securities issued.
- GlaxoSmithKline Savings Related Share Option Scheme: 129,432 securities issued.
Six schemes reported zero issuances during the period, maintaining their previous unallotted balances.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a regulatory disclosure of share option inventory.
Investor Verification Points
- Verify the total dilution impact of the 2,486,864 securities issued across the three active schemes during this six-month period.
- Confirm the total remaining pool of unallotted securities, which stands at approximately 38.5 million shares across all nine schemes.
- Note that the "Glaxo Wellcome International Share Option Scheme" holds the largest remaining balance of unallotted securities (13,267,156) with no recent activity.